What are the odds of developing Parkinson's disease?
Evidence quality 4.63/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, global adult
1 in 125
0.8% lifetime chance
range 1 in 200 to 1 in 83
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Parkinson’s sits in an odd middle zone on the fear-attention scale. It has the cultural signature of a "serious older-person disease" — tremor, the stooped posture, a handful of famous diagnoses from Muhammad Ali to Michael J. Fox to Ozzy Osbourne — but unlike Alzheimer’s, most adults under 60 rarely think about their own lifetime odds of developing it. When asked to guess, the typical answer is "pretty rare, maybe 1 in 500 or 1 in 1,000". The actual lifetime incidence is closer to 1 in 100 for men and 1 in 150 for women in high-income countries, which is much higher than the intuition but still an order of magnitude below dementia. Public awareness of Parkinson’s as a disease is high; awareness of personal odds is roughly calibrated, if slightly low.
Rough estimate: Most adults guess their personal lifetime PD risk at ~1 in 500 or lower
Source: editorial intuition, not polled
Actual
~11.8 million people living with Parkinson's worldwide (2021); ~90,000 new US cases per year
global adults
Show derivation
Anchored on two converging routes. (a) The Parkinson’s Foundation reports approximately 1.1 million Americans living with PD and nearly 90,000 new US diagnoses per year, against a US adult population of ~260 million — roughly 0.35 new cases per 1,000 adults per year, compounded over a 60-year adult lifetime and weighted for the heavy age-concentration above 65, this lands on ~1% lifetime incidence for men and ~0.67% for women (men are 1.5× more likely to develop PD than women per the Parkinson’s Foundation). (b) The WHO Parkinson disease fact sheet reports over 8.5 million people living with PD globally in 2019, with prevalence that has doubled in the past 25 years and is rapidly increasing; Dorsey et al. (Journal of Parkinson’s Disease, 2018) project this to 12 million by 2040 and possibly 17 million under scenarios of increased longevity and declining smoking. Globally, competing mortality in LMICs removes many adults from the denominator before peak PD-risk ages (70+), which pulls the population-averaged global lifetime incidence below the US-specific figure. Headline 0.008 (1 in 125) is a global-adult figure; the US-specific number is closer to 0.01 for men and 0.0067 for women. Uncertainty band 0.005 to 0.012 reflects the gap between the global average and the high-income-country figure, plus the fact that PD is systematically underdiagnosed (per the Parkinson’s Foundation, roughly 40% of US patients do not see a neurologist). Critically, this is INCIDENCE — the probability of being diagnosed with PD — not the probability of dying from PD. Parkinson’s is a chronic progressive disease; most patients die with it, not directly of it, and the proximal cause of death is usually aspiration pneumonia, cardiovascular disease, or a fall complication rather than PD-coded mortality.
Caveats: Two framing issues shape the headline number. First, this is INCIDENCE — the pro…
Two framing issues shape the headline number. First, this is INCIDENCE — the probability of being diagnosed with Parkinson’s disease in one’s lifetime — not mortality. PD is a chronic progressive disease with a typical 12-15 year course from diagnosis in high-income settings, and most patients die WITH it rather than OF it; the proximal cause on most death certificates is aspiration pneumonia, cardiovascular disease, or a fall complication. The WHO figure of 329,000 global PD deaths per year is therefore a floor, not a ceiling. Second, PD is systematically underdiagnosed: roughly 40% of US patients with PD do not see a neurologist at all, per the Parkinson’s Foundation, so diagnosed incidence is lower than true biological incidence. The headline 1-in-125 global figure sits between the global-average population baseline and the ~1-in-100 US-men figure; a US-specific reader should use the regional_breakdown entry that matches their demographics rather than the global headline. Personal factor multipliers are illustrative relative risks from the epidemiological literature and overlap with each other — family history, LRRK2 status, and pesticide exposure are not independent dimensions of risk.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| Global average | 1 in 125 |
Population-averaged global adult lifetime incidence; LMIC competing mortality pulls this figure below the high-income-country numbers |
| US men | 1 in 100 |
Roughly 1 in 100 lifetime incidence, consistent with the Parkinson's Foundation 90,000 new cases/year figure and the 1.5x male excess |
| US women | 1 in 149 |
Roughly 1 in 150 lifetime incidence; lower incidence despite longer life expectancy is one of the genuinely unexplained sex asymmetries in neurology |
| High pesticide exposure agricultural regions | 1 in 67 |
Occupational exposure to paraquat, rotenone, and organochlorines is the strongest established environmental risk factor; RR ~1.5-2.0 vs baseline |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Spinal cord injury
What are the odds of suffering a traumatic spinal cord injury that causes paralysis?
Benzo dependence
What are the odds of developing benzodiazepine dependence after a standard prescription?
Cat litter toxoplasmosis
What are the odds of acquiring a toxoplasma infection from cleaning a cat's litter box?
Childhood cancer diagnosis
What are the odds of a child being diagnosed with cancer before age 20?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
Roughly 11 million people were living with Parkinson’s disease worldwide as of the most recent WHO estimate, up from about 3 million in 1990 — a doubling in 25 years, with disability and death, in the WHO’s language, rapidly increasing. In the US, the Parkinson’s Foundation counts about 1.1 million Americans with PD and ~90,000 new diagnoses per year. Convert that to a lifetime figure and you get roughly 1 in 100 for men and 1 in 150 for women in high-income countries, with a global-average number closer to 1 in 125 once lower-income countries with heavier competing mortality are folded into the denominator. That puts Parkinson’s about an order of magnitude below lifetime dementia risk but well above the fears most people worry about actively — roughly 700× the lifetime odds of dying in a plane crash for a regular flyer, and about the same order of magnitude as the lifetime odds of dying in a car crash. Note that this is the probability of developing PD, not of dying from it: most people with Parkinson’s die with the disease, not directly of it, and the number coded on the death certificate is usually aspiration pneumonia or cardiovascular disease.
The interesting thing about Parkinson’s in the risk-factor literature is the smoking paradox. Across more than five decades and dozens of cohort and case-control studies, regular cigarette smokers have roughly half the PD risk of never-smokers, with a clear dose-response: more pack-years, lower risk. Coffee drinking shows a similar ~30% relative-risk reduction, stronger in men. Nobody recommends smoking as Parkinson’s prevention — the smoking mortality from lung cancer, COPD, and cardiovascular disease dwarfs the PD benefit by about two orders of magnitude — but the signal is one of the most robust inverse associations in chronic-disease epidemiology, and the mechanism is still actively debated (nicotine neuroprotection? a shared personality trait correlated with both smoking uptake and resistance to PD? selection bias from differential mortality removing smokers from the denominator before they reach peak PD-risk ages?). The Dorsey et al. Parkinson-pandemic paper explicitly lists declining smoking rates as one of the factors that could push global PD cases from 12 million to 17 million by 2040.
Where the number doesn’t apply: Parkinson’s is highly heterogeneous. The male:female ratio sits around 1.4-1.5:1 and the mechanism is not fully understood — women have longer life expectancy and ought to accumulate more PD on pure age-structure grounds, so the persistent male excess is a genuine biological asymmetry, not an artefact. Agricultural workers with chronic exposure to paraquat, rotenone, or organochlorine pesticides run roughly 1.5-2.0× baseline risk; this is the strongest established environmental factor and the clearest counterexample to the “idiopathic” label that applies to most cases. On the genetic side, carriers of the LRRK2 G2019S mutation — most common in Ashkenazi Jewish and North African Berber populations — have about a 10× relative risk and a cumulative incidence near 50% by age 80. Most PD, however, is idiopathic: no single environmental or genetic cause is identifiable for any individual case, and the bulk of lifetime risk is absorbed into the plain fact of living long enough to reach the ages where the substantia nigra starts losing dopaminergic neurons faster than it can compensate.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] Parkinson's Foundation — Parkinson's Disease Statistics
Parkinson's Disease Statistics- Statistic
~1.1 million Americans living with PD; ~90,000 new US cases/year; men 1.5x more likely than women; 4% diagnosed before age 50- Excerpt
“"An estimated 1.1 million people in the U.S. are living with Parkinson’s disease (PD). [...] Nearly an estimated 90,000 people in the U.S. are diagnosed with PD each year. [...] The incidence of Parkinson’s disease increases with age, but an estimated 4% of people with PD are diagnosed before age 50. [...] Men are 1.5 times more likely to have Parkinson’s disease than women. [...] More than 10 million people worldwide are estimated to be living with PD." ”
- Source data from
- 2024-01-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- 90,000 new US cases / ~260M US adults ≈ 0.35 per 1,000 adults/year. Naive 60-year compounding 1 − (1 − 3.5e-4)^60 ≈ 0.0208 or ~2%, but PD incidence is heavily concentrated in adults 65+ where the hazard is several-fold above the all-adult average. A life-table-weighted calculation for the cohort that actually reaches peak risk ages produces ~1% lifetime risk for US men and ~0.67% for US women (applying the 1.5× male excess). This source is the primary anchor for both the headline number and the sex split in regional_breakdown.
- Independence
- Parkinson’s Foundation synthesizes CDC/NCHS vital registration, the Parkinson’s Prevalence Project (Marras et al., 2018) cohort, and Medicare claims. Partially dependent with any GBD-derived global figure.
-
[2] World Health Organization — Parkinson disease — fact sheet
Parkinson disease — fact sheet- Statistic
Over 8.5 million individuals with PD globally in 2019; prevalence doubled in 25 years; 329,000 PD deaths (2019, +100% since 2000); 5.8 million DALYs (+81% since 2000)- Excerpt
“"The prevalence of PD has doubled in the past 25 years. Global estimates in 2019 showed over 8.5 million individuals with PD. [...] PD resulted in 5.8 million disability adjusted life years (DALYs), an increase of 81% since 2000 and caused 329 000 deaths, an increase of over 100% since 2000. [...] Globally, disability and death due to PD are rapidly increasing." ”
- Source data from
- 2023-08-09
- Accessed
- 2026-04-11 · archived copy
- Calculation
- 8.5M prevalent global cases across ~5.5B adults in 2019 = ~0.15% point prevalence in the global adult population. Because PD has a long residence time (mean survival from diagnosis is ~12-15 years in high-income settings), point prevalence systematically understates lifetime incidence. A rough conversion using residence-time correction produces ~0.5-0.8% global adult lifetime incidence, consistent with the headline 0.008 figure used here. The "doubled in 25 years" and "rapidly increasing" framing are the upward-pressure anchors that justify the high end of the uncertainty band.
- Independence
- WHO Parkinson fact sheet draws on GBD 2019 (Institute for Health Metrics and Evaluation) and the 2022 WHO technical brief on Parkinson disease. Partially dependent with Dorsey et al. below, which was an input to GBD’s Parkinson estimates.
-
[3] Dorsey, Sherer, Okun, Bloem — Journal of Parkinson's Disease — The Emerging Evidence of the Parkinson Pandemic
The Emerging Evidence of the Parkinson Pandemic- Statistic
PD doubled from ~3M to >6M (1990-2015); projected >12M by 2040; up to 17M under declining-smoking and industrialization scenarios- Excerpt
“"From 1990 to 2015, the number of people with Parkinson disease doubled to over 6 million. [...] This number is projected to double again to over 12 million by 2040. [...] Additional factors, including increasing longevity, declining smoking rates, and increasing industrialization, could raise the burden to over 17 million." ”
- Source data from
- 2018-12-18
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Used to anchor the trend line (doubling 1990-2015, doubling again by 2040) and the note that declining smoking rates are projected to increase PD burden. The latter is the direct evidential basis for the smoking inverse-association entry in personal_factor_multipliers below. Note: the paper’s 2015 figure of 6.2M and the WHO/GBD 2019 figure of 8.5M are consistent with the doubling-per-25-years trajectory.
- Independence
- Dorsey et al. 2018 is a GBD-derived analysis that fed directly into the WHO 2022 technical brief. Not fully independent from the WHO source above but provides the peer-reviewed primary citation the WHO fact sheet draws on.
-
[4] Ben-Shlomo, Darweesh, Llibre-Guerra, Marras, San Luciano, Tanner — The Lancet (via PMC) — The epidemiology of Parkinson's disease
The epidemiology of Parkinson's disease- Statistic
Male:female incidence ratio ~1.4:1; smoking shows dose-response inverse association with PD; pesticides (paraquat, rotenone) biochemically linked- Excerpt
“"The incidence, prevalence, and mortality risk of Parkinson’s disease is higher in men than in women by a ratio of approximately 1·4:1. [...] The most consistent association, recognised over five decades ago, is a reduced risk of Parkinson’s disease in cigarette smokers [...] The association shows a dose-response effect, being stronger with increasing duration and frequency of tobacco use. [...] Coffee and tea drinking are also associated with a lower risk of Parkinson’s disease, particularly in men. [...] Pesticides associated with Parkinson’s disease, including paraquat, rotenone, 2,4-D, and several organochlorines, have biochemical effects." ”
- Source data from
- 2024-04-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Primary peer-reviewed anchor for the personal_factor_multipliers block. The 1.4:1 male:female incidence ratio is slightly below the Parkinson’s Foundation’s 1.5× figure; both are within the meta-analytic range. The smoking inverse association of ~0.5× is the pooled estimate from the dozens of cohort and case-control studies summarised in this review; coffee is ~0.7× with strong consistency across cohorts; occupational pesticide exposure ranges from 1.5× to 2.0× depending on the chemical and the exposure definition. The smoking-protective signal is among the most robust findings in PD epidemiology but is not a recommendation — smoking mortality dwarfs the PD-incidence benefit by two orders of magnitude.
- Independence
- This Lancet review synthesises decades of PD case-control, cohort, and Mendelian-randomisation evidence. Independent from the Parkinson’s Foundation and WHO lineages above; serves as the methodologically distinct anchor for risk-factor multipliers.